EP3532086A1 - Neuartiges bispezifisches doppelsträngiges oligonukleotid zur behandlung von krebs - Google Patents

Neuartiges bispezifisches doppelsträngiges oligonukleotid zur behandlung von krebs

Info

Publication number
EP3532086A1
EP3532086A1 EP17800566.6A EP17800566A EP3532086A1 EP 3532086 A1 EP3532086 A1 EP 3532086A1 EP 17800566 A EP17800566 A EP 17800566A EP 3532086 A1 EP3532086 A1 EP 3532086A1
Authority
EP
European Patent Office
Prior art keywords
sirna
composition
siarh2ax
h2ax
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17800566.6A
Other languages
English (en)
French (fr)
Inventor
Florence Cabon
Hilary BROOKS
Stéphanie DELMAS
Maud CHUSSEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selexel
Original Assignee
Selexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1660441A external-priority patent/FR3058062A1/fr
Application filed by Selexel filed Critical Selexel
Publication of EP3532086A1 publication Critical patent/EP3532086A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar

Definitions

  • the present invention relates to a bispecific double-stranded oligonucleotide, at the same time targeting the androgen receptor and histone H2AX.
  • the cells of our organism undergo every day a large number of lesions of the DNA, provoked either by their metabolism which produces for example reactive species of the oxygen, or by their environment, in particular by the ionizing radiation or UV, agents physical or chemical, including certain drugs (https://en.wikipedia.org/wiki/DNA_damage_(naturally_occurring).)
  • Cells have developed several mechanisms of verification and repair during evolution to maintain the integrity of the genome
  • tumor suppressor proteins such as p53, orchestrate the blockage of cell division and the activation of repair mechanisms, and most lesions are normally repaired. Beyond a certain threshold of damage to the DNA however, the cell is no longer viable, enters apoptosis and dies.
  • cancer cells accumulate a large number of DNA lesions because their DNA repair mechanisms are frequently deficient and / or because they are more resistant to apoptosis than normal cells.
  • the threshold of damage to DNA leading to cell death is higher in a tumor cell than in a normal cell.
  • DNA lesions occur in a context where DNA is not linear but is compacted by nucleosomes consisting of histones. Some histones play a role of structure, others, like H2AX, are key in the functioning or the repair of the genome, H2AX is a histone expressed in all the cells of the body.
  • H2AX is a histone expressed in all the cells of the body.
  • the phosphorylation of H2AX then noted ⁇ 2 ⁇ , for example by proteins such as DNA-PK (DNA-dependent protein kinase), ATM (mutated in ataxia-telangiectasia) or ATR (ataxia telangiectasia and Rad3-related), is a major event. and early in DNA repair, which allows for the recruitment and assembly of many other proteins needed to repair the lesion.
  • DNA-PK DNA-dependent protein kinase
  • ATM mutated in ataxia-telangiectasia
  • ATR ataxia telangiectasia and Rad3-
  • H2AX can also be acetylated on lysine 36 by CBP / P300 and on threonine 101, and these two posttranslational modifications allow cells to survive ionizing radiation independently of the phosphorylation of H2AX.
  • Inhibiting the expression of H2AX in a cell, particularly in a cancer cell, is a method that prevents the repair of DNA damage.
  • inhibition of H2AX expression alone is not sufficient to induce cell death (Yuan and Chen, 2010).
  • Radiation therapy or certain chemotherapies have been developed to treat cancers by increasing the number of DNA lesions to exceed the threshold compatible with cell viability, threshold above which the apoptosis of the cancer cell is triggered. . These treatments work by inducing DNA damage and / or preventing the repair of lesions present in cancer cells. Radiation therapy is now essential in oncology since it is programmed in two thirds of treatment regimens, either alone or associated with surgery and / or chemotherapy. These treatments induce DNA damage, and in particular double-strand breaks (DSB).
  • DSB double-strand breaks
  • Cytotoxic chemotherapy aims to block the divisions of cancer cells and / or to induce their apoptosis. Most of these treatments lead to the accumulation of DNA lesions in the cell, either directly because of their mode of action. creates new lesions, either by preventing DNA repair or by keeping the cell at a cell cycle stage, or the repair processes are not very active. However, the many genome-testing and repair mechanisms that attempt to repair DNA damage reduce the effectiveness of these chemotherapy or radiation treatments.
  • the inhibition of H2AX thus provides a means of enhancing cell death induced by radiotherapy or chemotherapy treatments inducing DNA damage or preventing their repair.
  • AR The androgen receptor
  • AR is a transcription factor whose activity is regulated by its ligands. AR is expressed in both men and women by many cell types in most tissues and organs and in the hematopoietic system. AR regulates the expression of very many genes involved, for example, in proliferation, migration, survival, invasion, production of growth factors.
  • a deregulation of the expression or the functioning of AR for example and in a non-limiting way by overexpression, mutation, alternative splicing, post-translational modification or protein partner change, is described in the initiation, the maintenance and progression of various carcinomas, sarcomas, myelomas and leukemias, for example and in a non-limiting manner, certain cancers of the prostate, breast, ovary, bladder, liver, colon, stomach, adrenal and salivary glands, thymus, thyroid, uterus, peritoneum, pancreas, testes, kidney, skin, brain, nasopharynx, head and neck, meninges, lungs, testes, bones (Munoz et al., 2015).
  • Castration which prevents the production of AR ligands and therefore the transcriptional activity of AR, is a therapeutic strategy whose efficacy has been clinically demonstrated in prostate cancer.
  • the effectiveness of these treatments is transient and patients relapse systematically. There is therefore a real need for these cancers to improve the effectiveness of treatments targeting the AR signaling pathway.
  • AR is expressed in most cells of the body, and the deregulation of its expression or function is described in many cancers other than those of the prostate, the inhibition of the RA signaling pathway has not been shown to be sufficient to treat previously developed cancers in humans other than prostate cancer.
  • the proliferation of other cancer cells for example from breast tumors, melanomas or glioblastoma, which express AR at levels ranging from very low to high is not affected by the inhibition of this signaling path, as illustrated in the examples below.
  • the present invention is based on the unexpected results of the inventors according to which certain particular double-stranded oligonucleotides are bi-specific, since they simultaneously and specifically inhibit the expression of histone H2AX and that of the androgen receptor, which effectively inhibits the proliferation and survival of cells.
  • This effect of simultaneous inhibition of AR and H2AX can be enhanced by combining with a chemotherapy or radiation treatment that increases the number of DNA lesions or prevents their repair.
  • Micro RNAs are small double-stranded RNAs of about twenty nucleotides encoded by the genome of all eukaryotic organisms. After transcription and maturation, they are loaded into a protein complex: RNA Induced Silencing Complex (RISC).
  • RISC RNA Induced Silencing Complex
  • Hybridization with one or more mRNAs of nucleotides 2 to 8 inclusive of miRNA is of particular importance to trigger the mechanism of RNA interference.
  • a miRNA can hybridize with several target mRNAs and regulate their stability or translation. No computer or other tool can accurately predict the mRNAs regulated by a given miRNA (Gorski et al., 2017).
  • Interfering RNAs or Small Interfering RNAs are synthetic double-stranded oligoribonucleotides that when introduced into cells mimic the action of miRNAs, hybridize with their target mRNA, and trigger the RNA interference mechanism. Like miRNAs, they can hybridize incompletely with other mRNAs, and computer tools do not accurately predict among those many possible incomplete hybridizations those that interfere with mRNA and disrupt function. These so-called off-target effects are generally undesirable because they can produce potentially toxic biological effects that, if not predicable, must therefore be evaluated experimentally. Using multiple siRNAs simultaneously multiplies the number of potential off-target effects and therefore the risk of toxicity. To choose the sequence of a siRNA for inhibiting the expression of a gene of interest, there are many computer tools. These tools are designed so that the chosen siRNA hybridizes with only one mRNA so as to avoid off-target effects.
  • siRNAs are not comparable to any other type of oligonucleotide such as ribozymes, morpholinos, triple helix oligonucleotides, antisense RNA or antisense DNA oligonucleotides (ODN).
  • oligonucleotide such as ribozymes, morpholinos, triple helix oligonucleotides, antisense RNA or antisense DNA oligonucleotides (ODN).
  • the present invention is based on the unexpected results of the inventors according to which certain particular siRNAs described in Table 1, which hybridize perfectly with the mRNA encoding the receptor of androgens, which inhibit their expression, are bt-specific because they also partially hybridize with the mRNA encoding H2AX as described in Figure 1 and also specifically inhibit expression.
  • the present invention aims at providing a means for simultaneously inhibiting the expression of the androgen receptor and H2AX by the use of a bispecific siRNA.
  • the use of a bispecific AR-H2AX siRNA inhibiting both AR and H2AX, has a specific advantage over a siRNA targeting only AR, or a siRNA targeting only H2AX.
  • siRNAs are preferable to the combination of two siRNAs, one targeting AR and the other targeting H2AX, to limit the potentially toxic off-target effects of such a combination, and to facilitate the development clinical and industrial applications of this use.
  • the invention relates to a composition
  • a composition comprising at least one bispecific siRNA, defined as wholly or partially hybridizing with both an androgen receptor-encoding mRNA and an H2AX-encoding mRNA, such that this hybridization induces the degradation of these mRNAs or inhibits their translation
  • said siRNA being chosen from siRNA siARH2AX-1, SEQ ID NO 1 and SEQ ID NO 2 or siARH2AX-1b, SEQ ID NO 3 and SEQ ID NO 4 , as described in Table 1, for its use in the prevention and / or treatment of cancer, wherein said siRNA is used in combination with a therapy resulting in DNA damage or preventing their repair.
  • partial hybridization is meant the hybridization of a sufficient number of nucleotides of the bispecific siRNA of the invention with the sequence of the androgen receptor mRNA or with that of H2AX to cause either cleavage or inhibition of the translation of the mRNA with which it hybridizes, which leads to a decrease in the expression of the protein encoded by mRNA, a decrease that can be measured, for example, by a Western blot immunoassay or immunofluorescence immunoassay. indirect.
  • this hybridization may involve 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 nucleotides, or more if the siRNA has more nucleotides, for example 20, 21,
  • the percentage of hybridization can be between 30 and 95%.
  • said prevention and / or said treatment is carried out in a human patient or in a mammal.
  • siRNA sequences of the present invention are shown in Table 1.
  • the expression "at least 75% identity with a sequence" in Table 1 means 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96% 97%, 98%, 99% and 100%, including 79%, 81%, 84%, 86%, 90%, 95% and 99%.
  • siRNAs whose sequence is 100% identical to that of the siRNAs shown in Table 1 hybridize 100% with a region of the androgen receptor-encoding mRNA transcribed from exon 1. , all these siRNAs inhibit the expression of all forms of androgen receptor splicing expressed in cancer cells, including those partially or completely deletions of the ligand binding domain, such as, for example, the AR-V7 receptor variants expressed in certain cancers.
  • siRNA guide strand nucleation region siARH2AX-1 and siARH2AX-1b is also perfectly complementary to the mRNA encoding H2AX.
  • said bispecific AR-H2AX siRNA may have chemical modifications on one and / or the other strand, on one or more nucleotides located at the 3 'or 5' terminal ends, and / or or on one or more nucleotides constituting the internal skeleton.
  • said chemical modifications are located on the ribose and / or the base and / or the phosphoric acid.
  • Said chemical modifications comprise, for example, at least one substitution of the 2 'OH group of the ribose with a 2'-O-group.
  • RNA (2'OMe) or 2'-O-methoxyethyl (2'MOE) or 2'-fluoro (2'F) or 2'-fluoro-p ⁇ arabinonucleotide (FANA), an alkylation of oxygen in 2 aminoethyl-, guanidinoethyl-, cyanoethyi- or allyl, phosphodiester group replacement by phosphorothioate, alkylation or thiloation of one or more nucleotides of the oligonucleotide, replacement of a ribonucleotide with a deoxyribonucleotide, or replacement thereof of a nucleotide by a Locked Nucleic Acid (LNA).
  • LNA Locked Nucleic Acid
  • said bispecific AR-H2AX siRNA is devoid of chemical modification.
  • said siRNA is devoid of chemical modification, and comprises two deoxynucleotides overflowing at the 3 'end, in particular two deoxythymidines.
  • said siRNA is devoid of chemical modification, and does not comprise two deoxynucleotides overflowing at the 3 'end, in particular two deoxythymidines.
  • said bispecific AR-H2AX siRNA is formulated in a composition that allows its penetration into tumor cells.
  • a targeting agent is an agent that facilitates the penetration of a siRNA into the cells of the body.
  • This agent may be chemically conjugated to either strand of siRNA, or noncovalently associated with siRNA.
  • These include, for example, lipids, polymers, peptides, dendrimers, simple or complex sugars, polyethyleneimine derivatives, nanoparticles, magnetic spheres, or inorganic or organic nanostructures.
  • said composition contains an addressing molecule.
  • an addressing molecule is a molecule addressing the siRNA towards a particular cell type, for example endothelial cells or cancer cells.
  • An addressing molecule is not intended to penetrate the siRNA inside the cell or to penetrate with the siRNA but to increase its concentration to the outer membrane of the cell of interest.
  • an addressing molecule may be an aptamer, an antibody, transferrin, an RGD peptide, the ligand of a receptor, this targeting molecule interacting or binding to a molecule expressed on the surface of the targeted cells, such as for example and without limitation a receptor, an integrin, a membrane antigen such as for example PSMA (Prostate Specific Membrane Antigen) or the CD36 receiver.
  • a targeting molecule such as for example and without limitation a receptor, an integrin, a membrane antigen such as for example PSMA (Prostate Specific Membrane Antigen) or the CD36 receiver.
  • this targeting molecule is a CD36 receptor ligand, for example oxidized LDLs, or hexareiine peptide or a long chain fatty acid (more than 16 carbons), or a mixture of these components two by two or three to three.
  • CD36 receptor ligand for example oxidized LDLs, or hexareiine peptide or a long chain fatty acid (more than 16 carbons), or a mixture of these components two by two or three to three.
  • the abovementioned composition contains oxidized LDLs in a weight: weight ratio of 1 siRNA for 0.01 to 10 oxidized LDLs and preferably 0.1 to 1, or hexarelin peptide, in a weight: weight ratio of 1 siRNA for 0.01 to 10 hexarelin, preferably 0.1 to 1.
  • the addressing molecule may be either associated with siRNA without a covalent bond, or covalently coupled with either siRNA strand, or incorporated into a targeting agent, for example a nanoparticle or a liposome containing siRNA, so as to address the targeting agent to the target cell or tissue.
  • said composition contains neither a targeting agent nor an addressing molecule.
  • said composition contains a vectorization agent but no addressing molecule.
  • said composition contains an addressing molecule but no targeting agent.
  • the targeting molecule is in particular a CD36 ligand, and more particularly oxidized LDL or helix 'areline.
  • said composition contains a targeting agent and an addressing molecule.
  • the targeting molecule is in particular a CD36 ligand, and more particularly oxidized LDL or hexarelin.
  • said composition containing said bispecific siAR-H2AX siRNA is formulated to be administered locally or ioco regionally, in particular by intratumoral administration, in single dose or by repeated injections, intermittently or else still continuously by the use of an external pump or implantable, or any other device, or biodegradable compound allowing a slow and continuous release of the composition in the vicinity or in the tumor to be treated (intra-tumor administration).
  • the continuous mode of administration aims to keep the concentration of the siRNA substantially constant throughout the entire period of administration of the siRNA in the tissue if it is a local or loco regional administration or in blood and peripheral tissues if it is a systemic administration.
  • the phrase "maintain substantially constant" means that the concentration of siRNA in the blood and peripheral tissues may vary slightly depending on the metabolism of the individual receiving said composition.
  • continuous is meant the uninterrupted administration of the composition for a period of 1 day to several months, for example 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days , 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 1 year, 2 years.
  • the siRNA delivered in a continuous mode of delivery is delivered continuously for a period of time greater than or equal to 2 days.
  • the siRNA delivered according to a continuous administration mode is delivered without the administration being interrupted beyond the time necessary to recharge or exchange the device delivering the siRNA, for example 4 hours, for a duration of administration ranging from 2 days to 1 year, for example 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 1 year.
  • the siRNA delivered according to a continuous mode of administration is delivered in successive cycles, interrupted by a period without treatment ranging from more than 24 hours to a few weeks, each cycle being defined by continuous administration. without interruption greater than the time required to recharge or exchange the device delivering the siRNA, for example 4 hours, and for a duration of administration ranging from 2 days to 1 month.
  • intermittent administration is understood to mean any mode of administration in which the period of administration of the product (for example, 10 seconds, 1 minute, 1 hour, 2 hours, 4 hours, etc.) is followed by a period during which the product is not administered (for example, 1 hour, 2 hours, 6 hours, 24 hours, 1 week ). It may, for example and without limitation, be a bolus administration, single or repeated over time or a slow infusion over a period of a few hours, leading over time to significant variation the concentration of the product in the tissue or organism.
  • siARNA bispecific siRNA which distributes them in several tissues and organs, is therefore advantageous for treating cancers that are metastasized or likely to become so.
  • systemic means that the siRNA is conveyed in the body to act at a distance from the place where it is administered, as opposed to a local or loco-regional administration, in particular as opposed to an administration. intratumoral.
  • the systemic distribution in the body is obtained by any method that results in a passage of siRNA in extracellular fluids such as blood, lymph or cerebrospinal fluid, that the compound containing the siRNA is ingested (orally).
  • systemic administration can be carried out by administering a single or repeated dose of said composition, intermittently or else by the use of an external or implantable pump, or any other device, or biodegradable compound allowing a slow and continuous release of said composition, such that the siARH2AX bispecific siRNA is systemically transported via the extracellular fluids in the body.
  • said method of systemic administration is selected from the subcutaneous, intravenous, intraperitoneal, intramuscular, intradermal, intranasal, intravaginal, intrarectal, sublingual, intrathecal, intracerebral, oral administration mode, and is especially subcutaneous.
  • said mode of administration is continuous, subcutaneously.
  • the siARH2AXs according to the invention are administered systemically or locally by being formulated in an acidic pH buffer solution.
  • a buffer solution according to the present invention provides the pH stability of the siRNA dilution solution. Examples of such buffers are given in Table 3.
  • the pH of the buffer solution is acid, ranging from pH 3 to pH 7, preferably from pH 5 to pH 6.5 and preferentially to pH 6.
  • the buffer solution is a citrate or histidine buffer at pH 6.
  • the SiARH2AX siRNAs according to the invention are administered systemically or locally in an acidic pH buffer solution supplemented with cations derived from inorganic or organic salts. These cations within the meaning of the invention are not constituents of the buffer solution, they are not intended to ensure a buffer effect, but they are added to this buffer solution.
  • these cations are, for example and without limitation, polyamines, in particular putrescine, and / or spermidine, and / or spermine, and / or salts whose cation is chosen from metal cations such as, for example, Zn2 +, Co2 + , Cu2 +, Mn2 +, Ca2 +, Mg2 +, Fe2 +, the counterion being of any nature, for example a chloride, nitrate, sulfate or carbonate ion.
  • the buffer solution contains MgCl 2, ZnCl 2, MnCl 2, or a two-by-two mixture of these salts, or a mixture of the three salts.
  • the concentration of each cation is from 0.02 mM to 200 mM, preferably from 0.05 to 100 mM and preferably from 1 to 50 mM.
  • the cations are added to a buffer solution which is a citrate buffer or a histidine buffer.
  • a buffer solution which is a citrate buffer or a histidine buffer.
  • the pH of this solution is 6.
  • said composition is formulated for a mode of administration of siRNA siRNA bispecific at a therapeutically effective dose, and in particular at doses of 0.005 mg / kg / day to 30 mg / kg / day, in particular 0.01 mg / kg / day to 10 mg / kg / day.
  • "0.005 mg / kg / day to 30 mg / kg / day” means all doses ranging from 0.005 mg / kg / day to 30 mg / kg / day, eg 0.008; 0.01; 0.05; 0.1; 0.5; 1.0; 1.5; 10.0; 10.5; 14.0; 14.5; 20; 20.5; 25; 25.5; 29.5 mg / kg / day.
  • said composition is used in combination with a treatment inducing DNA lesions or preventing their repair and said treatment being chosen from radiotherapy and / or chemotherapy.
  • Radiotherapy refers to a method of locoregional treatment of cancers, using radiation to destroy cancer cells by blocking their ability to multiply.
  • the technique and the modalities of radiotherapeutic treatment, in particular the doses of radiation delivered, are adapted according to the cancer and the patient.
  • Radiotherapy is the best known and the most used.
  • the radiation source outside the patient, produces high energy X-ray beams and electron beams.
  • - Brachytherapy also called brachytherapy
  • brachytherapy is a local radiotherapy by implantation of grains or radioactive needles. Such a therapy is especially used in the treatment of prostate cancers.
  • - Vector-based metabolic radiotherapy is a radiotherapy technique based on oral administration or injection of a radio-labeled radio-labeled agent.
  • the radioactive isotope will bind preferentially to the diseased target cells.
  • iodine 131 binds to the thyroid.
  • the metastatic bone pain can thus be treated, for example, by injection of samarium 153, strontium-labeled liquid strontium chloride 894, or radium-223 chloride.
  • Chemotherapy refers to a drug treatment (cytostatic and antineoplastic chemotherapeutic agents) against cancer.
  • said chemotherapy resulting in lesions of the DNA or preventing their repair is carried out using at least one chemotherapeutic agent chosen from: alkylating agents, anti-metabolites, cytotoxic antibiotics, inhibitors topoisomerase I inhibitors, topoisomerase II inhibitors, anti-tumor antibiotics, genotoxic agents, PARP inhibitors (poly (ADP-ribose) polymerase), microtubule-forming and dissociation inhibiting agents, such as vinca alkaloids, taxanes or epothilones,
  • a chemotherapeutic agent is chosen in particular from:
  • said therapy resulting in lesions of DNA or preventing their repair and the administration of said composition containing at least one bispecific SiAR-H2AX siRNA are simultaneous or successive.
  • the term "successive” is understood according to the invention of the expression “separated, spread over time”.
  • the invention also relates to a combination product containing:
  • siRNA chosen from: if ARH2AX-1, siARH2AX-1b and
  • At least one chemotherapeutic agent causing damage to the DNA or preventing its repair
  • the invention also relates to a combination product containing:
  • siRNA chosen from: siARH2AX-1, siARH2AX-1b and
  • At least one radiopharmaceutical agent which causes a lesion of the DNA at least one radiopharmaceutical agent which causes a lesion of the DNA
  • the invention also provides a combination product formulated for intermittent or continuous local administration containing:
  • siRNA chosen from: siARH2AX-1, siARH2AX-1b and
  • the cancer is a primary tumor, or a metastasis of a primary tumor.
  • the cancer is adrenocortical, esophageal, gastric, basal cell, thyroid, or uterine carcinoma, astrocytoma, glioblastoma, oligodendroglioma, meningioma, thymoma, lymphoma, melanoma, or non-melanoma skin cancer, leukemia, mesothelioma, cholangiocarcinoma, myeloma, gastrointestinal cancer, bladder, breast, cervix, head and neck, non-malignant lung small cells, ovary, pancreas, prostate, testis, thymus, kidney, salivary gland, endometrium, anus, colon, appendix, mouth , bronchi and / or upper airways, bile duct, nasal and paranasal cavity, brain, heart, stomach, liver, throat, tongue, lips, nasopharynx, esophagus, bones, par
  • said composition comprising at least one bispecific siRNA, said siRNA hybridizing wholly or partially with both an androgen receptor-encoding mRNA and an H2AX-encoding mRNA, such that hybridization induces the degradation of these mRNAs or inhibits their translation
  • said siRNA being chosen from siRNA siARH2AX-1, SEQ ID NO 1 and SEQ ID NO 2 or siARH2AX-Ib, SEQ ID NO 3 and SEQ ID NO 4, such as described in Table 1, is used alone for its use in the prevention and / or treatment of cancer, in particular adrenocortical, esophageal, gastric carcinoma, basal cells, thyroid or uterine carcinoma, astrocytoma , glioblastoma, oligodendroglioma, meningioma, thymoma, lymphoma, melanoma or non-melanoma skin cancer, leukemia, mesothelioma, chol
  • said prevention and / or said treatment is carried out in a human patient or in a mammal.
  • said bispecific AR-H2AX siRNA can have chemical modifications on one and / or the other strand, on one or more nucleotides located at the 3 'or 5' terminal ends, and / or on one or more nucleotides constituting the internal skeleton. Examples of chemical modifications can be found in the section entitled "Chemical modifications”.
  • said bispecific AR-H2AX siRNA is devoid of chemical modification.
  • said bispecific AR-H2AX siRNA is devoid of chemical modification and comprises two deoxynucleotides overflowing at the 3 'end, in particular two deoxyfhymidines.
  • said bispecific AR-H2AX siRNA is devoid of chemical modification and does not comprise two deoxynucleotides bridging at the 3 'end, in particular two deoxythymidines.
  • said composition contains neither a targeting agent nor an addressing molecule or contains a targeting agent but no targeting molecule or contains an addressing molecule but no targeting agent or contains a targeting agent.
  • vectorization and an addressing molecule can be found in the section entitled "Vectorization agents and addressing molecules"
  • the addressing molecule may be either associated with siRNA without a covalent bond, or covalently coupled with either siRNA strand, or incorporated into a targeting agent, for example a nanoparticle or a liposome containing siRNA, so as to address the targeting agent to the target cell or tissue.
  • composition containing siRNA bispecific siARH2AX is formulated for a systemic, local, or loco-regional administration, in single dose or repeated intermittently or continuously.
  • the siARH2AXs according to the invention are administered systemically or locally by being formulated in an acidic pH buffer solution.
  • acidic pH buffer solution examples of such buffers are given in Table 3.
  • the buffer solution is a citrate or histidine buffer.
  • the acidic pH buffer solution is supplemented or not with cations from inorganic or organic salts. Examples of cations can be found in the section entitled "Buffer and cations”.
  • the concentration of each cation is from 0.02 mM to 200 mM, preferably from 0.05 to 100 mM and preferably from 1 to 50 mM.
  • the cations are added to a buffer solution which is a citrate buffer or a histidine buffer.
  • said composition is formulated for a mode of administration of siRNA siRNA bispecific at a therapeutically effective dose, and in particular at doses of 0.005 mg / kg / day to 30 mg / kg / day, in particular 0.01 mg / kg / day to 10 mg / kg / day.
  • "0.005 mg / kg / day to 30 mg / kg / day” means all doses ranging from 0.005 mg / kg / day to 30 mg / kg / day, eg 0.008; 0.01; 0.05; 0.1; 0.5; 1.0; 1.5; 10.0; 10.5; 14.0; 14.5; 20; 20.5; 25; 25.5; 29.5 mg / kg / day.
  • the present invention also relates to compositions containing at least one siRNA selected from siRNA siARH2AX-1, SEQ ID NO 1 and SEQ ID NO 2 or siARH2AX-1b, SEQ ID NO 3 and SEQ ID NO 4. as described in Table 1, said siRNA being in an acidic pH buffer solution. Examples of such buffers are given in Table 3.
  • said composition is formulated for a systemic, local or loco-regional administration mode, in single dose or repeated intermittently or continuously.
  • the buffer solution is a citrate or histidine buffer.
  • the acidic pH buffer solution is supplemented or not with cations from inorganic or organic salts. Examples of cations can be found in the section entitled "Buffer and cations”.
  • the concentration of each cation is from 0.02 mM to 200 mM, preferably from 0.05 to 100 mM and preferably from 1 to 50 mM.
  • the cations are added to a buffer solution which is a citrate buffer or a histidine buffer.
  • the present invention also relates to compositions containing at least one siRNA selected from siRNA siARH2AX-1, SEQ ID NO 1 and SEQ ID NO 2 or siARH2AX- 1b, of SEQ ID No. 3 and SEQ ID NO 4, said siRNA being in a buffer solution at acidic pH, said buffer solution being in particular a citrate or histidine buffer, said buffer solution being supplemented with cations originating from inorganic or organic salts, in particular salt whose cation is chosen from polyamines, especially chosen from spermine, spermidine or putrescine, or in particular from a salt whose cation is chosen from metal cations, in particular chosen from zinc, cobalt, copper and manganese salts, calcium, magnesium or iron, especially manganese, zinc, magnesium, alone or in combination two to two or three to three.
  • siRNA siARH2AX-1 siRNA siARH2AX-1, SEQ ID NO 1 and SEQ ID NO 2 or siARH2AX- 1b
  • said bispecific AR-H2AX siRNA can have chemical modifications on one and / or the other strand, on one or more nucleotides located at the 3 'or 5' terminal ends, and / or on one or more nucleotides constituting the internal skeleton. Examples of chemical modifications can be found in the section entitled "Chemical modifications”.
  • said bispecific AR-H2AX siRNA is devoid of chemical modification.
  • said bispecific AR-H2AX siRNA is devoid of chemical modification and comprises two deoxynucleotides bridging at the 3 'end, in particular two deoxythymidines.
  • said bispecific AR-H2AX siRNA is devoid of chemical modification and does not comprise two deoxynucleotides bridging at the 3 'end, in particular two deoxythymidines.
  • said composition contains neither a targeting agent nor an addressing molecule or contains a targeting agent but no targeting molecule or contains an addressing molecule but no targeting agent or contains a targeting agent.
  • vectorization and an addressing molecule can be found in the section entitled "Vectorization agents and addressing molecules"
  • the addressing molecule may be either associated with siRNA without a covalent bond, or covalently coupled with either siRNA strand, or incorporated into a targeting agent, for example a nanoparticle or a liposome containing siRNA, so as to address the targeting agent to the target cell or tissue.
  • said composition is used in combination with a treatment inducing DNA lesions or preventing their repair and said treatment being chosen from radiotherapy and / or chemotherapy.
  • a treatment inducing DNA lesions or preventing their repair and said treatment being chosen from radiotherapy and / or chemotherapy.
  • radiotherapy or chemotherapeutic agents can be found in the section entitled "association with treatment inducing DNA damage or preventing its repair”.
  • said bispecific siARNA siRNA bispecific included in said composition is at a therapeutically effective dose, and in particular at doses of 0.005 mg / kg / day to 30 mg / kg / day, in particular 0.01 mg / kg / day at 10 mg / kg / day.
  • "0.005 mg / kg / day to 30 mg / kg / day” means all doses ranging from 0.005 mg / kg / day to 30 mg / kg / day, eg 0.008; 0.01; 0.05; 0.1; 0.5; 1.0; 1.5; 10.0; 10.5; 14.0; 14.5; 20; 20.5; 25; 25.5; 29.5 mg / kg / day.
  • the first column indicates the name of the siRNA.
  • the second column indicates the composition of the siRNA, consisting of the combination of a strand-type oligonucleotide (1b) or an oligonucleotide whose sequence has at least 75% identity with this strand-type oligonucleotide ( respectively lb),
  • oligonucleotide 2 a strand-type oligonucleotide 2 (respectively 2b) or an oligonucleotide whose sequence has at least 75% identity with this strand-type oligonucleotide 2 (respectively 2b).
  • the third column indicates the numbering of the oligonucleotide as filed.
  • the fourth column indicates the sequence in the 5 'to 3' orientation.
  • the notation [dT] [dT] is used to indicate the presence of two overflowing deoxythymidines.
  • the target sequence i.e., the sequence of the mRNA to which the siRNA guide strand hybridizes
  • the target sequence i.e., the sequence of the mRNA to which the siRNA guide strand hybridizes
  • the target sequence of these siRNA is present in humans in all the mRNAs encoding the androgen receptor, whether this receptor is wild, that it has splicing variations leading to the partial deletion or total hormone binding domain (variant AR-V7 for example) or that it has one of the mutations described in prostate cancer.
  • the second column indicates the tissue origin of the cells
  • the level of mRNA encoding AR was measured by RT-qPCR in these lines and normalized by that of the mRNA encoding the cyclophilin A (delta CT method).
  • the results, given in the third column, are expressed in arbitrary units, the level measured in the 22RV1 cells being considered as 100,000.
  • Figure 1 Schematic representation of the method of quantification of a siRNA by RT qPCR. Example of reference range.
  • FIG. 2 Comparison of the complementarity of the siRNA sequences of the invention and siRNA siRNA with the mRNA encoding the androgen receptor in humans and that encoding H2AX.
  • the underlined bases are those which are perfectly complementary to those of the guide strand of the indicated siRNAs.
  • the siRNAs indicated are composed of oligonucleotides 100% identical to those described in Table 1.
  • the gray boxes indicate the nucleation region (seed region), that is, the nucleotides ranging from
  • Figure 3 Quantification by RT-qPCR of mRNAs encoding AR and H2AX 48h after transfection in C4-2 cells of control siRNA (Cont, black bars), siAR2 (gray bars) or siARH2AX-1
  • each mRNA is expressed relative to that measured in cells transfected with a siRNA control.
  • FIG. 4 Quantification by RT-qPCR of the mRNAs Encoding AR, PSA and H2AX 72h After Transfection in the LNCaP or C4-2 Cells of a Control siRNA (Cont, Black Bars), SiAR7 (Dark Gray Bars), or SiARH2AX -l (white bars). The level of expression of each mRNA is expressed relative to that measured in cells transfected with a siRNA control.
  • FIG. 5 Quantification by RT-qPCR of mRNAs Encoding AR and H2AX 72h After Transfection in LNCaP or MDA MB -453 Cells of a Control siRNA (Cont, Black Bars), SiH2AX (Dark Gray Bars), SiARh (Bars) light gray), or siARH2AX-1 (white bars). For each cell type, the level of expression of each mRNA is expressed relative to that measured in cells transfected with a siRNA control.
  • Figure 6 immunoblotting of the expression of AR and H2AX 72h by western blot after transfection of C4-2 cells by one of the following siRNAs: Control (Cont), siARH2AX-1, siRNA, siH2AX, or a mixture of both siRNA siH2AX and siARh.
  • Figure 7 Immuno detection by western blot of the expression of AR, H2AX and ⁇ 2 ⁇ 72h after transfection of PC3 cells by one of the following siRNAs: Control (Cont), siAR7 or siARH2AX-1.
  • FIG. 8 Immuno detection of ⁇ 2 ⁇ (first column) and 53BP1 (second column) in C4-2 cells treated for 6 h with bleomycin (10 ⁇ l) or the vehicle added 72 h after transfection of cells by a control siRNA (Cont. ), siARNA siAR7, or siARH2AX-1.
  • Figure 9 Measurement of cell viability by a WST1 test of MDA MB231 or C4-2 cells 90h after transfection of a siRNA control (black bars) of siAR2 (gray bars) or siARH2AX-1 (bars) white). The measured values are related to the average of the values measured in the control condition (control siRNA, vehicle).
  • Figure 10 Left panel: Viability of 22RV1, MDA MB-453, U87, WM266-4 and MDA MB231 cells measured by a 72 hr WST1 test after transfection of a siRNA control (Cont), siARh, siH2AX or siARH2AX .
  • Right panel LNCaP or C4-2 cell viability measured by a 72 hr WST1 test after transfection of a control siRNA (Cont), siAR7, or siARH2AX. For each line, the results are related to cell viability in the control condition.
  • Figure 11 Measurement of cell viability by a WST1 test of C4-2 cells transfected for 48 h by a control siRNA (black bars), siAR2 (gray bars) or siARH2AX-1 (white bars) and then incubated for 48 h in a medium containing 10 ⁇ of bleomycin or 10 ⁇ of etoposide or the vehicle. The measured values are related to the average of the values measured in the control condition (control siRNA, vehicle).
  • FIG. 12 Viability of the LNCaP or C4-2 cells, measured by a WST1 metabolic test, 48 h after treatment with bleomycin 10 ⁇ or by its vehicle added 24 h after transfection of the cells by a control siRNA (Cont) or by siARH2AX-1 .
  • the viability measurements of the different samples are related to the average of the values measured in the cells cultured under the control condition (siRNA control without bleomycin) considered as 100%.
  • FIG. 13 Viability of MDA MB231 and WM266-4 cells, measured by a WST1 metabolic test, 48h after treatment with etioposide 40 ⁇ or by its vehicle added 24 hours after transfection of the cells by a control siRNA (Cont, black bars) , siRNA siH2AX (dark gray bars), siARh siRNA (light gray bars) or siARH2AX-1 (white bars).
  • the viability measurements of the different samples are related to the average of the values measured in the cells cultured under the control condition (siRNA control without bleomycin) considered as 100%.
  • Figure 14 Inhibition of bone metastases from prostate cancer by continuous systemic administration of if ARH2AX-1.
  • Figure 16 Effect of a composition comprising siRNA siH2AX-1 and a CD36 receptor ligand administered as a single dose on siRNA distribution in vivo.
  • Figure 17 Effect of a composition comprising siRNA siH2AX-1 and a CD36 receptor ligand administered systemically subcutaneously continuously on the distribution of siRNA in vivo.
  • Osmotic pumps delivering continuously for 3 days 2mg / kg / day of siRNA siARH2AX-1 were implanted subcutaneously in mice bearing human prostatic tumors 22RV1.
  • the siRNA was formulated either in a saline solution (154 mM NaCl, gray bars) or in 10 mM citrate buffer at pH 6 containing 1 ⁇ M MgCl 2 and supplemented with oxidized LDL (siARH2AX-1: oxidized LDL 1: 0.1, weight / weight) (black bars).
  • SiARH2AX-1 was quantified by RT-qPCR at the end of the 3 days of treatment.
  • the mean of each group (3 mice per group) was related to the mean values in the serum of the NaCl group.
  • the axis of ordinates indicates the concentration of siARH2AX-1 relative to that measured in the serum of the mice having received the siRNA diluted in a solution of NaCl.
  • Figures 18 Volume versus time of C4-2 tumors developing by nude mice treated three times a week by the vehicle (DMSO) (black diamonds), etoposide at a dose of 5 mg / kg (gray diamonds clear), or 10 mg / kg (dark gray diamonds), or treated with continuous subcutaneous administration of siRNA siARH2AX-1 (white triangles), administered alone or in combination with etoposide at a dose of 5 (light gray triangles) or 10 (dark gray triangles) mg / kg three times a week.
  • DMSO black diamonds
  • etoposide at a dose of 5 mg / kg gray diamonds clear
  • 10 mg / kg dark gray diamonds
  • siRNA siARH2AX-1 white triangles
  • siRNA not hybridizing with any known mRNA was used.
  • This siRNA, Cont is composed of the following two oligonucleotides:
  • siRNA inhibiting AR Four siRNA inhibiting AR are used:
  • siRNA siARH2AX- is composed of two oligonucleotides SEQ NO 1 and SEQ NO 2 as indicated in Table 1.
  • SiARNA siRNA described in application PCT / FR2002 / 003843, is composed of the following two oligonucleotides: Two other siRNAs hybridizing with AR mRNA but not with H2AX mRNA were used. SiARh hybridizes with a sequence of the first exon of AR, siAR7 with a sequence of the 7 ° exon of AR. These siRNAs are composed of the following two oligonucleotides:
  • siRNA, siH2AX, hybridizing with H2AX mRNA but not with AR mRNA was also used.
  • This siRNA is composed of the following two oligonucleotides:
  • the cells are cultured in DMEM or RPMI supplemented with 10% fetal calf serum, or as recommended by the ATCC. When indicated, they are transfected with siRNA using lipofectamine (Life Technologies), following the provider's protocol. The number of living cells after the indicated treatments was quantified by measuring their metabolic activity by the WST1 test according to the supplier's indications (Roche).
  • RNAs extracted by a conventional phenol-chloroform method Trizol
  • the amount of RNA was normalized by measuring the mRNA encoding cyclophilin A which is not regulated by AR (delta delta CT method).
  • Immuno-detection of tubulin or actin is used to ensure that comparable amounts of protein are analyzed under the different conditions.
  • RT-qPCR quantitative PCR
  • a specific stem-loop primer with 8 protruding nucleotides is synthesized, the 8 nucleotides being complementary to the 8 nucleotides of the 3 'end of the siRNA (antisense) guide strand.
  • the product obtained is amplified by PCR using two primers, one hybridizing with the region corresponding to the loop of the reverse transcription primer.
  • the 12 nucleotides at 3 'of the second primer having a DNA sequence corresponding to the 12 nucleotides of the 5' end of the newly synthesized cDNA after reverse transcription of the siRNA guide strand. Detection of the amplification is carried out continuously by the degradation of a Taqman fluorescent probe or by incorporation of SybrGreen.
  • FIG. 1 shows schematically the RT-qPCR method and an exemplary range showing the relationship between the number of copies present in the reaction and the CT (cycle threshold or amplification threshold) obtained.
  • the biological samples in which the siRNAs are quantified are either serum or total RNAs extracted from known weight tissue fragments thought to contain siRNA. These RNAs are extracted by conventional methods such as by the phenol-chloroform method (trizol extraction). After extraction, they are diluted in water;
  • the CT values obtained for each sample are compared with those obtained for the range.
  • Tumors are obtained by subcutaneous injection of tumor cells into the flank of Nude mice. Only animals on which tumor uptake is found are included in the study and randomized to receive treatment or control treatment.
  • Etoposide When indicated, Etoposide, diluted in DMSO and then adjusted to the required concentration in a 154 mM NaCl solution, is injected intraperitoneally at the indicated dose, 3 times per week.
  • siRNAs are diluted in water containing 154mM NaCl or in the indicated buffer.
  • the continuous administration of siRNA is carried out by implantation of an Alzet osmotic pump subcutaneously on the back of the mice, on the opposite side to the tumor when the mice wear one.
  • the concentration of siRNA in the pump is adjusted to deliver the indicated amount in mg / kg / day taking into account the pump flow rate indicated by the manufacturer.
  • the animals are sacrificed, the serum, the tumors and different tissues are dissected, the extracted RNAs and the siRNAs present in these RNAs are quantified.
  • siRNA siARH2AX-1 and siARH2AX-1b of the invention are bispecific.
  • FIG. 2 The alignments shown in Figure 2 show that the 19 siARH2AX-1 bases and the 21 siAR2 bases are perfectly complementary to the AR mRNA. This figure also shows that 17 bases out of 19 of siARH2AX-1 and 17 bases out of 21 of siAR2 hybridize with those of the mRNA encoding H2AX. The presence of two deoxythymidines brimming with these siRNAs has no effect on the hybridization of these siRNAs.
  • siRNA nucleation region of siARH2AX-1 and siARH2AX-1b that is to say nucleotides 2 to 8 inclusive of the 5 'to 3' sequence of their guide strand, (gray box in FIG. 1) is perfectly complementary. (7 bases out of 7, ie 100%) of the mRNA of H2AX. This complementarity is however only partial, from 5 bases out of 7, that is only 71% for siAR2, the nucleotides in position 2 and 3 of siAR2 not being complementary to the mRNA of H2AX. This difference results in a functional difference between siARH2AX-1 and siAR2 as shown in Figure 3.
  • siRNA siARH2AX-1 and siAR2 inhibit AR expression in a similar manner.
  • SiAR2 siRNA whose nucleation region is only partially (71%) complementary to the H2AX mRNA is considerably less effective at inhibiting the expression of H2AX than the siRNA siARH2AX-1 whose nucleation region is perfectly complementary to the H2AX mRNA.
  • the LNCaP or C4-2 tumor cells were transfected with the following siRNAs: Cont, siAR7 or siARH2AX-1.
  • the analysis of the mRNAs encoding AR, coding for the Antigen-specific Prostate, or PSA, which is a gene regulated by the androgen receptor, and those encoding H2AX shows that in both lines, siAR7 and siARH2AX-1 inhibit the expression of AR and PSA, but that only siARH2AX-1 also inhibits the expression of H2AX to more than 90%.
  • siRNAs Cont, siH2AX, siArh, siARH2AX-1.
  • siARh inhibits AR but not H2AX
  • siH2AX inhibits H2AX but not AR.
  • the siRNA siARH2AX-1 alone inhibits the expression of the two mRNAs encoding AR and H2AX.
  • siRNAs Cont, siARH2AX-1, siArh, siH2AX, and a mixture ( 1: 1) of both siRNA siARh and siH2AX.
  • siARh inhibits AR but not H2AX
  • siH2AX inhibits H2AX but not AR
  • the mixture of both siRNA inhibits AR and H2AX.
  • the siRNA siARH2AX-1 alone inhibits the expression of both AR and H2AX proteins.
  • the PC3 tumor cells which express weakly AR, were transfected with the following siRNAs: Cont, siAR7 or siARH2AX-1. 72 hours after transfection, the expression of AR and H2AX proteins was measured. It is observed that the expression of H2AX is inhibited by siARH2AX-1 but by siAR7. Inhibition of H2AX is accompanied by inhibition of its phosphorylated form ⁇ 2 ⁇ .
  • siRNA siARH2AX-1 has the ability to inhibit both AR and H2AX at the same time.
  • siARH2AX-1 siRNA is much more effective than siRNA siARNA in inhibiting H2AX expression.
  • a difference of two bases in the nucleation region of these two siRNAs profoundly modifies their ability to inhibit H2AX.
  • siARH2AX-1 Inhibition of H2AX by siARH2AX-1 occurs in cells expressing AR strongly (LNCaP, C4-2), intermediate (MDA MB253) or weakly (PC3).
  • Example 3 Inhibition of H2AX prevents the recruitment of 53BP1 on bleomycin-induced DNA lesions and decreases cell viability.
  • C4-2 cells were transfected with a control siRNA or siARH2AX-1. 72 hours after transfection, the cells were then treated for 6 hours with 10 ⁇ l of bleomycin or the corresponding vehicle.
  • siAR7 transfected cells In siAR7 transfected cells, bleomycin induces an increase in ⁇ 2 ⁇ labeling and recruitment of 53BP1.
  • siARH2AX-1 In cells transfected with siARH2AX-1, the expression of H2AX is very small compared to the control condition whereas the expression of 53BP1 is comparable. After treatment with bleomycin, siARH2AX-1 transfected cells were not seen to increase H2AX or to recruit 53BP1 to focal points of repair of DNA lesions.
  • siRNA siARH2AX inhibits DNA repair.
  • siRNA siARH2AX-1 reduces cell viability regardless of the level of AR expression.
  • siRNA Control Cont
  • siH2AX siARh
  • siARH2AX-1 in the right panel, the cells were transfected with siRNA Control (Cont), siH2AX, siARh, or siARH2AX-1 and in the right panel. by a siRNA Control, siAR7 or siARH2AX-l.
  • the siRNA siARh and siAR7 inhibit the proliferation of cells that strongly express AR (22RV1, C4-2, LNCaP) but not other lines expressing intermediate or low levels of AR (MDA MB 453, MDA MB 231, WM 266 -4, U87).
  • siRNA siARH2AX-1 inhibits the proliferation of all cell lines, regardless of the level of AR expression, and regardless of the effect on their proliferation of AR inhibition by the siRNA siARh that does not inhibit H2AX whereas siRNA siH2AX that only inhibits H2AX expression without affecting AR has little effect on cell proliferation, regardless of lineage.
  • siRNA siARH2AX-1 alone inhibits cell proliferation, whether it depends or does not depend on AR expression and that AR is expressed very strongly at an intermediate level. or very weakly in these cells.
  • Example 5 The effects of siRNA siARH2AX-1 and DNA damage inducing agents are potentiated, regardless of the level of AR expression.
  • siRNA cont 48 hours after transfection of C4-2 cells by siRNA cont, siAR2 or siARH2AX-1, the cells were treated with a vehicle or with etoposide ( ⁇ ) or bleomycin ( ⁇ ), chemotherapy agents inducing DNA damage. 48 hours after addition of the chemotherapy agents, it is observed that the combination of siRNA siRNA with one or other of these agents does not produce a significantly greater inhibitory effect on viability than that measured by the chemotherapeutic agent alone. In contrast, the effects of siARH2AX-1 and either of the chemotherapeutic agents potentiate to inhibit cell viability.
  • MDA MB 231 or WM266-4 cells that express weakly AR were transfected with a control siRNA (Cont), siH2AX, siArh, or siARH2AX-1. 24 hours after transfection, the cells were treated with 40 ⁇ l of eioposide or by the vehicle, and the cell viability, relative to that of the cells under controlled conditions, was measured by a WST1 test 48 h later. It is observed that in both lines, etoposide inhibits cell proliferation. When this treatment is associated with inhibition of H2AX by siH2AX, or with inhibition of AR by siRNA siARh, there is no amplification of the effects of etoposide on proliferation. On the other hand, etoposide and siARH2AX-1 treatments potentiate when combined.
  • siRH2AX-1 siRNA is much more effective than siRNA siRNA in inhibiting H2AX expression and cell viability, including in cells expressing low AR.
  • siARH2AX-1 potentiates the inhibitory effects of viability produced by chemotherapies.
  • Example 6 Administration of siARH2AX-1 to tumor-bearing mice inhibits metastatic spread.
  • siARNA siARNA2-1 subcutaneously continues to mice with human prostatic tumors 22RV1 to inhibit the expression of the androgen receptor in the bones of mice ( Figure 14 left panel). This inhibition is accompanied by a decrease in the number of mice spontaneously developing bone metastases of these tumors and a decrease in the size of these tumors, evaluated by the level of expression of a human mRNA (HRPT) in the tumors. bone ( Figure 14 right panel).
  • HRPT human mRNA
  • siRNA siARH2AX-1 thus allows it to be delivered in the metastases of a cancer developing in bone, to inhibit the expression of the target siRNA gene in the bone and to to limit the implantation and / or the development of metastases.
  • osmotic pumps continuously delivering siARH2AX-1 at a dose of 2 mg / kg / day diluted either in saline solution (154 mM NaCl) or in solution in citrate buffer at pH 6 containing 10 mM of MgCl2 (Cit / mg), were implanted subcutaneously in tumor-bearing mice. After 3 days, siARH2AX-1 was quantified by RT-qPCR in serum, various organs, and tumors. It is found that compared to the saline formulation, the citrate buffer formulation at pH 6 supplemented with 10 mM MgC12 significantly increases the concentration of siARH2AX-1 in tissues and tumors.
  • the CD36 receptor is expressed to the outer membrane of endothelial cells of many tumor cells and other cell types such as macrophages. This CD36 receptor binds different classes of ligands, such as oxidized LDLs or hexarelin peptide.
  • siRNA siARH2AX-1 at the dose of 0.12 mg / kg, formulated in a solution of 154 mM NaCl (control group, denoted NaCl) or in a 10 mM citrate buffer pH 6
  • Addition of 0.02 mM hexarelin peptide (Cit / Hexarelin) or 30 nM oxidized LDL (Cit / LDL) was administered as a bolus subcutaneous injection to groups of adult mice.
  • siRNA siARH2AX-1 a dose of 2 mg / kg / day.
  • the siRNA was formulated either in 154 mM NaCl solution, or in 10 mM citrate buffer pH 6 containing oxidized LDL (siARH2AX-1: LDLox in ratio 1: 0.1, weight: weight).
  • the concentration of siARH2AX-1 was measured after 3 days of treatment in serum, different organs and tumors. It is found that the addition of oxidized LDL increases the concentration of siARH2AX-1 in serum, different organs and tumors.
  • Example 8 The combination of siARH2AX-1 and a DNA damage inducing agent potentiates the effect of each of these separately administered treatments on tumor development.
  • an osmotic pump was implanted into 22RV1 human prostate tumor-bearing mice for subcutaneous and continuous administration for 22 days from day 1 of siRNA siARH2AX-1 to dose of 2mg / kg / day formulated in 10mM citrate buffer pH 6 containing 10mM MgCl2, or the vehicle alone.
  • the mice received an intraperitoneal injection of etoposide at a dose of 5 or 10 mg / kg or the vehicle and this treatment was repeated twice a week until sacrifice of the mice. It is observed that etoposide at 5 mg / kg only slightly inhibits tumor development.
  • siRNA siARH2AX-1 is as effective as the high dose of etoposide without causing weight loss.
  • the combination of treatment with etoposide and siARH2AX-1 potentiates the effect of these two treatments taken separately.
  • siRNA siARH2AX-1 effectively inhibits tumor development, with no significant toxic effect in animals, and that the combination of this treatment with low, non-toxic doses of an agent inducing DNA amplifies inhibition of tumor growth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
EP17800566.6A 2016-10-27 2017-10-27 Neuartiges bispezifisches doppelsträngiges oligonukleotid zur behandlung von krebs Withdrawn EP3532086A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1660441A FR3058062A1 (fr) 2016-10-27 2016-10-27 Nouvelle utilisation d'un oligonucleotide double brin
FR1757591 2017-08-08
PCT/FR2017/052976 WO2018078303A1 (fr) 2016-10-27 2017-10-27 Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers

Publications (1)

Publication Number Publication Date
EP3532086A1 true EP3532086A1 (de) 2019-09-04

Family

ID=60382462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17800566.6A Withdrawn EP3532086A1 (de) 2016-10-27 2017-10-27 Neuartiges bispezifisches doppelsträngiges oligonukleotid zur behandlung von krebs

Country Status (6)

Country Link
US (1) US20210292755A1 (de)
EP (1) EP3532086A1 (de)
JP (1) JP2020500217A (de)
CN (1) CN110114076A (de)
CA (1) CA3041630A1 (de)
WO (1) WO2018078303A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169576A1 (de) 2018-03-23 2023-04-26 University of Massachusetts Gentherapeutika zur behandlung von knochenerkrankungen
CN115025216B (zh) * 2022-05-10 2023-08-11 浙江颐核医疗科技有限公司 一种用于癌症治疗的组合物和方法
WO2024220863A1 (en) * 2023-04-20 2024-10-24 University Of Massachusetts Rna therapeutics for fibrodysplasia ossificans progressiva and uses thereof
WO2025041340A1 (ja) * 2023-08-24 2025-02-27 株式会社Dti 二重特異性核酸

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040366A2 (fr) * 2001-11-09 2003-05-15 Centre National De La Recherche Scientifique -Cnrs- Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
FR2835837A1 (fr) * 2003-02-06 2003-08-15 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4526228B2 (ja) * 2002-11-22 2010-08-18 隆 森田 ＲＮＡｉによる新規治療法および治療剤
FR2835838B1 (fr) * 2003-02-06 2007-11-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer
EP2283870A1 (de) * 2009-07-31 2011-02-16 Centre National de la Recherche Scientifique Oligonukleotide zur Hemmung der Zellenmigration
US20140099257A1 (en) * 2012-10-05 2014-04-10 Cornell University Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
BR112017014090A2 (pt) * 2014-12-29 2018-03-06 Bonac Corporation composição, e, métodos para produção de uma composição e estabilização de uma molécula de ácido nucleico.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040366A2 (fr) * 2001-11-09 2003-05-15 Centre National De La Recherche Scientifique -Cnrs- Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
FR2835837A1 (fr) * 2003-02-06 2003-08-15 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAYMOND J. ANDERSEN ET AL: "Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor", CANCER CELL, vol. 17, no. 6, 1 June 2010 (2010-06-01), US, pages 535 - 546, XP055223053, ISSN: 1535-6108, DOI: 10.1016/j.ccr.2010.04.027 *
S B HAKE ET AL: "Linking the epigenetic 'language' of covalent histone modifications to cancer", BRITISH JOURNAL OF CANCER, vol. 90, no. 4, 1 February 2004 (2004-02-01), GB, pages 761 - 769, XP055446953, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6601575 *
See also references of WO2018078303A1 *

Also Published As

Publication number Publication date
CN110114076A (zh) 2019-08-09
WO2018078303A1 (fr) 2018-05-03
JP2020500217A (ja) 2020-01-09
CA3041630A1 (fr) 2018-05-03
US20210292755A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
Roberti et al. Epigenetics in cancer therapy and nanomedicine
Xing et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo
Sowery et al. Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy
EP2419535B1 (de) Freisetzung von oligonukleotid-funktionalisierten nanopartikeln
Réjiba et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer
Bonnet et al. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition
EP3532086A1 (de) Neuartiges bispezifisches doppelsträngiges oligonukleotid zur behandlung von krebs
Pandey et al. Nucleotide biosynthesis arrest by silencing SHMT1 function via vitamin B6-coupled vector and effects on tumor growth inhibition
Sousa et al. Gold nanoconjugates for miRNA modulation in cancer therapy: from miRNA silencing to miRNA mimics
Beloor et al. Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA
Silva-Cázares et al. Lipid-based nanoparticles for the therapeutic delivery of non-coding RNAs in breast cancer
EP3532088A1 (de) Verwendung von sirna zur behandlung von krebs
Yoshida et al. MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma
Wagner Tumor‐targeted Delivery of Anti‐microRNA for Cancer Therapy: pHLIP is Key
CA3006827A1 (en) Monocarboxylate transporter 4 (mct4) antisense oligonucleotide (aso) inhibitors for use as therapeutics in the treatment of cancer
Wu et al. Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer
Hong et al. Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon
Cina et al. A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-Driven Non–small Cell Lung Cancer
KR20230138462A (ko) 암 치료를 위한 템플릿 지시된 면역조절
Yao et al. Folic acid-targeted macrophage membrane-coated carbon quantum dot nanoplatform for dual drug and gene delivery in metastatic osteosarcoma therapy
Kim et al. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer
Bhatia et al. miRNAs are now starring in “No Time to Die: Overcoming the chemoresistance in cancer”
Keyvani et al. Insight into RNA-based therapies for ovarian cancer
Remant et al. Cationic lipopolymer based siRNA delivery for experimental lung cancer treatment
Zhong et al. Progress in antitumor mechanisms and applications of phenformin

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210423

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20210923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220204